Claritas_updatedlogo.png
Claritas Pharmaceuticals Issues Letter to Shareholders
May 11, 2021 08:30 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, May 11, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE (TSXV): CLAS and OTC: KALTF) (the “Company” or “Claritas”) today issued the following...
Claritas_updatedlogo.png
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
April 21, 2021 05:00 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, April 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into...
Claritas_updatedlogo.png
Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH
April 14, 2021 13:51 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into...
Claritas_updatedlogo.png
Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients
April 08, 2021 08:15 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that, based on...
Claritas_updatedlogo.png
Kalytera Therapeutics Inc. Completes Name Change to Claritas Pharmaceuticals, Inc.
April 02, 2021 15:00 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, April 02, 2021 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that the Company has changed...
Claritas_updatedlogo.png
Claritas Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107
April 01, 2021 08:30 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
Claritas_updatedlogo.png
Claritas Announces Addition of Perenlei Enkhbaatar, M.D., Ph.D., FAHA to the Company’s Board of Directors
March 26, 2021 08:30 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, March 26, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
Claritas_updatedlogo.png
Claritas Announces Appointment of Robert Farrell, J.D. as Chairman of the Company’s Board of Directors
March 18, 2021 08:30 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, March 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
Claritas_updatedlogo.png
Claritas Announces Completion of Canine Toxicology Studies
March 17, 2021 08:30 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, March 17, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
Claritas_updatedlogo.png
Claritas Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107
March 12, 2021 08:30 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, March 12, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...